Drug Pipeline & Clinical Insights – October 2026

October’s Drug Pipeline & Clinical Insights highlights three new specialty therapies that expand treatment options for patients with complex and rare conditions. This month, we look at what these approvals could mean for pharmacy benefits, including cost, access, and appropriate use. 

  • 2 Min read

  • October 20, 2026

Clinical Insights

Key Highlights

  • 3 key new drug approvals: Isembyld (apitegromab-mstn), a muscle-targeted treatment for spinal muscular atrophy; Atebrioz (zilurgisertib), the third therapy approved for fibrodysplasia ossificans progressiva; and Etcamah (camizestrant), an oral therapy that enables an ESR1-guided treatment switch in advanced breast cancer. 
  • This month focuses on specialty therapies: All three new drug approvals are expected to be managed through specialty pharmacy, and two of the three treat rare disease conditions. 
Key New Drug Approvals 

Isembyld (apitegromab-mstn) 

Approval Date: 09/11/2026
Cost*: ~$37,900 per month 

Key Considerations: 
  • New treatment for spinal muscular atrophy (SMA) in adults and children 2 years and older who are currently receiving a survival motor neuron 2-targeted therapy. 
  • Administered by IV infusion every 4 weeks. 
  • At parity with existing SMA therapies (Zolgensma®, Itvisma®, Spinraza® and Evrysdi®), with no clear advantage in efficacy or safety. 

LucyRx Perspective: With an annual cost of approximately $454,700 and no clear advantage over existing SMA therapies, Isembyld is a candidate for utilization management, including prior authorization and step therapy, to help ensure appropriate use.

Atebrioz (zilurgisertib) 

Approval Date: 09/25/2026
Cost*: ~$42,480 per month 

Key Considerations: 
  • Once-daily oral ALK2 inhibitor for fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder, in patients 12 years and older. 
  • Third agent approved for FOP, following Pasatru® (garetosmab-grts) and Sohonos® (palovarotene), with a unique mechanism of action. 

LucyRx Perspective: Atebrioz adds a third, oral option for an ultra-rare condition, and pricing will be important to monitor once it is announced, along with specialty management, prior authorization, and quantity limits as it enters the market.

Etcamah (camizestrant)

Approval Date: 09/04/2026
Cost*: ~$20,800 per month 

Key Considerations: 
  • Oral estrogen receptor antagonist (75 mg once daily) used with a CDK4/6 inhibitor for adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer when an ESR1 mutation is detected during aromatase inhibitor and CDK4/6 inhibitor therapy 
  • Replaces the aromatase inhibitor while the CDK4/6 inhibitor continues, enabling an ESR1-guided treatment switch before disease progression 
  • Carries a Boxed Warning for serious heart rhythm problems when used with ribociclib or other drugs that prolong the heart’s electrical recovery time 

LucyRx Perspective: Etcamah introduces a new biomarker-guided treatment option in a disease state with significant treatment needs. By targeting the estrogen receptor, Etcamah reduces estrogen-dependent signaling that promotes breast cancer cell growth and allows treatment to be adjusted when an ESR1 mutation is detected.  

*Cost: List price is provided for general reference and does not reflect rebates, discounts, insurance coverage, copay support, or actual plan or member cost. 

Tags

Drug Pipeline Oncology Pharmacy benefits Rare Diseases specialty pharmacy

Recommended Reads

Business benefits professionals reviewing pharmacy benefit options and partnership requirements for employer health plans.

What Makes a Pharmacy Benefit Solution Easier for TPAs to Stand Behind?

Third-party administrators put their own client relationships at stake when recommending a pharmacy benefit manager. Learn which capabilities help TPAs evaluate PBM partners, explain benefit strategies confidently and maintain accountability from implementation through renewal.

When Women’s Health Reaches the Prescription, the Pharmacy Benefit Still Has Work to Do

Women’s health programs can improve clinical access, but prescription barriers can still interrupt treatment. Employers and benefits leaders should evaluate affordability, coverage, medication availability and how quickly access problems are resolved.
Benefits professionals reviewing pharmacy benefit contract terms, data access and implementation requirements to assess how much control employers have over their PBM strategy.

PBM Flexibility Is Not the Same as Control: What TPAs Should Test

Pharmacy benefit options have limited value if contract restrictions or operational barriers prevent employers from using them. This article outlines how TPAs can assess decision-making information, contractual rights and implementation capabilities before recommending a PBM.
Benefits and implementation teams reviewing a PBM transition plan, data requirements and go-live responsibilities before an employer pharmacy benefit launch.

Implementation Is Part of the Sale: What TPAs Should Test Before Recommending a PBM

A PBM transition can put a TPA’s client relationship at risk if eligibility errors, prescription disruptions or unclear responsibilities emerge at go-live. This checklist outlines five areas TPAs should test before recommending a PBM to an employer.
Employer benefits leader evaluating specialty pharmacy performance, costs, access, and member outcomes

How Should a Specialty Pharmacy Earn Its Role?

Specialty pharmacy can materially affect employer plan costs, access, and treatment continuity. This article outlines the measures benefits leaders can use to evaluate pharmacy channels based on evidence rather than affiliation.

Projected Savings vs. Realized Savings: What Employers Should Ask

Employers need to know whether a pharmacy savings figure represents an opportunity or an actual result. This article explains how to evaluate savings methodology, assumptions, and outcomes.
GLP-1 medication representing employer coverage and cost decisions

A Better Way to Think About GLP-1 Strategy

GLP-1 coverage no longer has to be an all-or-nothing decision. Employers can evaluate access, clinical support, costs, and benefit visibility to build a strategy that works for their plan and the people who rely on it.
Woman with glucose monitor

Diabetes Affordability is About More Than One Prescription

Diabetes affordability extends beyond insulin. Learn how employers can evaluate medication costs, GLP-1s, monitoring devices, coverage rules, and member support across the full diabetes regimen.
Pharmacist and Patient

Is Your Pharmacy Benefit Still Working as Intended?

A pharmacy benefit can perform as designed and still fall behind the market. Learn how employers can evaluate costs, member access, plan design, and PBM performance—and decide whether to stay, improve the current strategy, or explore a change.
Doctors chart

Disclosure Won. Now What?

PBM transparency gives employers greater visibility into pharmacy costs—but disclosure is only the beginning. Learn how plan sponsors can turn better information into greater control, accountability, and measurable results.
PreviousNext
Business benefits professionals reviewing pharmacy benefit options and partnership requirements for employer health plans.

What Makes a Pharmacy Benefit Solution Easier for TPAs to Stand Behind?

Third-party administrators put their own client relationships at stake when recommending a pharmacy benefit manager. Learn which capabilities help TPAs evaluate PBM partners, explain benefit strategies confidently and maintain accountability from implementation through renewal.

When Women’s Health Reaches the Prescription, the Pharmacy Benefit Still Has Work to Do

Women’s health programs can improve clinical access, but prescription barriers can still interrupt treatment. Employers and benefits leaders should evaluate affordability, coverage, medication availability and how quickly access problems are resolved.
Benefits professionals reviewing pharmacy benefit contract terms, data access and implementation requirements to assess how much control employers have over their PBM strategy.

PBM Flexibility Is Not the Same as Control: What TPAs Should Test

Pharmacy benefit options have limited value if contract restrictions or operational barriers prevent employers from using them. This article outlines how TPAs can assess decision-making information, contractual rights and implementation capabilities before recommending a PBM.
Benefits and implementation teams reviewing a PBM transition plan, data requirements and go-live responsibilities before an employer pharmacy benefit launch.

Implementation Is Part of the Sale: What TPAs Should Test Before Recommending a PBM

A PBM transition can put a TPA’s client relationship at risk if eligibility errors, prescription disruptions or unclear responsibilities emerge at go-live. This checklist outlines five areas TPAs should test before recommending a PBM to an employer.
Employer benefits leader evaluating specialty pharmacy performance, costs, access, and member outcomes

How Should a Specialty Pharmacy Earn Its Role?

Specialty pharmacy can materially affect employer plan costs, access, and treatment continuity. This article outlines the measures benefits leaders can use to evaluate pharmacy channels based on evidence rather than affiliation.

Projected Savings vs. Realized Savings: What Employers Should Ask

Employers need to know whether a pharmacy savings figure represents an opportunity or an actual result. This article explains how to evaluate savings methodology, assumptions, and outcomes.
GLP-1 medication representing employer coverage and cost decisions

A Better Way to Think About GLP-1 Strategy

GLP-1 coverage no longer has to be an all-or-nothing decision. Employers can evaluate access, clinical support, costs, and benefit visibility to build a strategy that works for their plan and the people who rely on it.
Woman with glucose monitor

Diabetes Affordability is About More Than One Prescription

Diabetes affordability extends beyond insulin. Learn how employers can evaluate medication costs, GLP-1s, monitoring devices, coverage rules, and member support across the full diabetes regimen.
Pharmacist and Patient

Is Your Pharmacy Benefit Still Working as Intended?

A pharmacy benefit can perform as designed and still fall behind the market. Learn how employers can evaluate costs, member access, plan design, and PBM performance—and decide whether to stay, improve the current strategy, or explore a change.
PreviousNext

LucyRx is an independent, modern pharmacy benefit manager with the scale of an enterprise serving more than 9 million members nationwide.

Follow us

Linkedin Linkedin Tiktok Tiktok Instagram Instagram
URAC Accreditation

Copyright © 2026 by LucyRx. All Rights Reserved | Privacy Policy | Terms of Use | Members Rights

How Should a Specialty Pharmacy Earn Its Role?Employer benefits leader evaluating specialty pharmacy performance, costs, access, and member outcomesBenefits and implementation teams reviewing a PBM transition plan, data requirements and go-live responsibilities before an employer pharmacy benefit launch.Implementation Is Part of the Sale: What TPAs Should Test Before Recommending...

Download the PBM Reform Readiness Checklist

Download the GLP-1 Planning Checklist